Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Orthomyxoviruses Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

NCT03232567
View directory record Official record
Conditions
Influenza
Interventions
NasoVAX
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

NCT01715909
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159
View directory record Official record
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 28, 2026, 2:12 AM EDT
Not listed Phase 4 Interventional

Optimizing Influenza Vaccination in Surgical Oncology Patients

NCT01698177
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Immune Responses to Influenza Vaccination

NCT03346772
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Influenza vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

NCT00753272
View directory record Official record
Conditions
Influenza
Interventions
GSK Bio's influenza vaccine GSK2186877A, Fluarix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
43,695 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
63
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mobile, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Not applicable Interventional

School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities

NCT01224301
View directory record Official record
Conditions
Immunizations, Vaccination, Influenza, School Health
Interventions
School based flu vaccine: Low intensity, School based flu vaccine: High intensity
Behavioral
Lead sponsor
Monroe County Department of Public Health
Other
Eligibility
4 Years to 13 Years
Enrollment
25,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

NCT00978120
View directory record Official record
Conditions
H1N1 Influenza Virus
Interventions
H1N1 vaccine high dose, H1N1 vaccine low dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

NCT01691339
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 28, 2026, 2:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

NCT00001681
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

NCT00489931
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions
VRC-AVIDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00743275
View directory record Official record
Conditions
Influenza
Interventions
Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

NCT00192140
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 49 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial to Collect Safety Data and Sera for Immunogenicity Testing

NCT00389857
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine (Fluzone®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 36 Months
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 28, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Memory for Flu Facts and Myths and Effects on Vaccine Intentions

NCT00296270
View directory record Official record
Conditions
Influenza Vaccines
Interventions
Memory for truth
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 26 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2006 · Synced Sep 28, 2026, 2:12 AM EDT
Completed No phase listed Observational

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

NCT01024673
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 28, 2026, 2:12 AM EDT